Repeated intravenous injections in non-human primates demonstrate preclinical safety of an anti-inflammatory phosphorus-based dendrimer

References

• Bonfanti U, Lamparelli D, Colombo P, Bernardi C. 2009. Hematology and serum chemistry parameters in juvenile cynomolgus monkeys (Macaca fascicularis) of Mauritius origin: comparison between purpose-bred and captured animals. J Med Primatol 38:228–35
   PubMed Web of Science ®Google Scholar
• Bontrop RE. 2001. Non-human primates: essential partners in biomedical research. Immunol Rev 183:5–9
   PubMed Web of Science ®Google Scholar
• Bosch X. 2011. Dendrimers to treat rheumatoid arthritis. ACS Nano 5:6779–85
   PubMed Web of Science ®Google Scholar
• Cohen CR, Brown J, Moscicki AB, Bukisi EA, Paull JR, Price CF, et al. 2011. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 gel (VivaGel®) in healthy young women administered twice daily for 14 days. PLoS One 6:e16258
   Google Scholar
• Colvin VL. 2003. The potential environmental impact of engineered nanomaterials. Nat Biotechnol 21:1166–70
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, Germolec DR, Weaver JL. 2009. Evaluation of nanoparticle immunotoxicity. Nat Nanotech 4:411–14
   PubMed Web of Science ®Google Scholar
• Fruchon S, Caminade AM, Abadie C, Davignon JL, Combette JM, Turrin CO, et al. 2013. An azabisphosphonate-capped poly(phosphorhydrazone) dendrimer for the treatment of endotoxin-induced uveitis. Molecules 18:9305–16
   PubMed Web of Science ®Google Scholar
• Fruchon S, Poupot M, Martinet L, Turrin CO, Majoral JP, Fournié JJ, et al. 2009. Anti-inflammatory and immuno-suppressive activation of human monocytes by a bio-active dendrimer. J Leukocyte Biol 85:553–62
   PubMed Web of Science ®Google Scholar
• Griffe L, Poupot M, Marchand P, Maraval A, Turrin CO, Rolland O, et al. 2007. Multiplication of human natural killer cells by nanosized phosphonate-capped dendrimers. Angew Chem Int Edit 47:2523–6
   Web of Science ®Google Scholar
• Hayder M, Fruchon S, Fournié JJ, Poupot M, Poupot R. 2011a. Anti-inflammatory properties of dendrimers per se. Scientific World J 11:1367–82
   Web of Science ®Google Scholar
• Hayder M, Poupot M, Baron M, Nigon D, Turrin CO, Caminade AM, et al. 2011b. A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. Sci Transl Med 3:81ra35
   PubMed Web of Science ®Google Scholar
• Heidel JD, Yu Z, Liu YCJ, Rele SM, Liang Y, Zeidan RK, et al. 2007. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104:5715–21
   PubMed Web of Science ®Google Scholar
• Hoet PHM, Nemmar A, Nemery B. 2004. Health impact of nanomaterials? Nat Biotechnol 22:104–19
   PubMed Web of Science ®Google Scholar
• Hünig T. 2012. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 12:317–18
   PubMed Web of Science ®Google Scholar
• Jain K, Kesharwani P, Jain NK. 2010. Dendrimer toxicity: let’s meet the challenge. Int J Pharm 394:122–42
   PubMed Web of Science ®Google Scholar
• Lafont BAP, Gloeckler L, D’Hautcourt JL, Gut JP, Aubertin AM. 2000. One-round determination of seven leukocyte subsets in rhesus macaque blood by flow cytometry. Cytometry 41:193–202
   PubMedGoogle Scholar
• Lappin PB, Black LE. 2003. Immune modulator studies in primates: the utility of flow cytometry and immunohistochemistry in the identification and characterization of immunotoxicity. Toxicol Pathol 31:111–18
   PubMedGoogle Scholar
• Leah E. 2011. Dendrimer drug mends monocytes. Nat Rev Rheumatol 7:376
   Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26
   PubMed Web of Science ®Google Scholar
• McCarthy TD, Karellas P, Henderson SA, Giannis M, O’Keefe DF, Heery G, et al. 2005. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbocides for HIV and STI prevention. Mol Pharm 2:312–18
   PubMed Web of Science ®Google Scholar
• McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, et al. 2011. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel®) in sexually active young women (MNT-004). AIDS 25:1057–64
   PubMed Web of Science ®Google Scholar
• Mestas J, Hughes CCW. 2004. Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731–8
   PubMed Web of Science ®Google Scholar
• Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL. 2006. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 50:1696–700
   PubMed Web of Science ®Google Scholar
• Portevin D, Poupot M, Rolland O, Turrin CO, Fournié JJ, Majoral JP, et al. 2009. Regulatory activity of azabisphosphonate-capped dendrimers on human CD4+ T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy. J Transl Med 7:82--94
   PubMed Web of Science ®Google Scholar
• Poupot M, Griffe L, Marchand P, Maraval A, Rolland O, Martinet L, et al. 2006. Design of phosphorylated dendritic architectures to promote human monocyte activation. FASEB J 20:2339–51
   PubMed Web of Science ®Google Scholar
• Rolland O, Turrin CO, Caminade AM, Majoral JP. 2009. Dendrimers and nanomedicine: multivalency in action. New J Chem 33:1809–24
   Web of Science ®Google Scholar
• Sakurai F, Nakamura S, Akitomo K, Shibata H, Terao K, Kawabata K, et al. 2008. Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates. Mol Ther 16:726–33
   PubMed Web of Science ®Google Scholar
• Tarrant J. 2010. Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use. Toxicol Sci 117:4–16
   PubMed Web of Science ®Google Scholar
• Thiagarajan G, Greish K, Ghandehari H. 2013. Charge affects the oral toxicity of poly(amidoamine) dendrimers. Eur J Pharm Biopharm 84:330–4
   PubMed Web of Science ®Google Scholar
• Verdier F, Aujoulat M, Condevaux F, Descotes J. 1995. Determination of lymphocyte subsets and cytokine levels in Cynomolgus monkeys. Toxicology 105:81–90
   PubMed Web of Science ®Google Scholar
• Wagner V, Dullaart A, Bock AK, Zweck A. 2006. The emerging nanomedicine landscape. Nat Biotechnol 24:1211–17
   PubMed Web of Science ®Google Scholar
• Ye L, Yong KT, Liu L, Roy I, Hu R, Zhu J, et al. 2012. A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots. Nat Nanotech 7:453–8
   PubMed Web of Science ®Google Scholar
• Yoshino N, Ami Y, Terao K, Tashiro F, Honda M. 2000. Upgrading of flow cytometry analysis for absolute counts, cytokines and other antigenic molecules of Cynomolgus monkeys (Macaca fascicularis) by using anti-human cross-reactive antibodies. Exp Anim 49:97–110
   PubMed Web of Science ®Google Scholar